Find clinical trials for Ovarian Cancer in Charlotte, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma

Endometrial Cancer

Cancer

Breast Cancer

Fallopian Tube Cancer

Non-Small-Cell Lung Carcinoma

Triple Negative Breast Cancer

Ovarian Cancer trials near Charlotte, NC, USA:

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objecti ...

Enrolling

Primary Peritoneal Cancer

Platinum-refractory Ovarian Cancer

Drug: Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin

Drug: Platinum chemotherapy: carboplatin (preferred) or cisplatin

Phase 3

Genelux

Charlotte, North Carolina, United States and 30 other locations

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....

Active, not recruiting

Advanced Ovarian Cancer

FIGO Stage III-IV

Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca

Charlotte, North Carolina, United States and 176 other locations

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (RAMP 301)

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (I...

Enrolling

Low Grade Serous Ovarian Cancer

Drug: Defactinib

Drug: Letrozole

Phase 3

Verastem

Charlotte, North Carolina, United States and 104 other locations

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST)

Ovarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes. The high expression of vascular ...

Active, not recruiting

Ovarian Neoplasms

Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

Drug: Dostarlimab-Placebo

Drug: Standard of care

Phase 3

Tesaro

Charlotte, North Carolina, United States and 181 other locations

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 2)

The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian...

Enrolling

Ovarian Cancer

Drug: INCB123667

Drug: Investigator's choice of chemotherapy

Phase 3

Incyte

Charlotte, North Carolina, United States and 109 other locations

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)

survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by the investigator. The hypotheses are that pembro...

Active, not recruiting

Carcinoma, Ovarian Epithelial

Fallopian Tube Neoplasms

Drug: Bevacizumab

Biological: Pembrolizumab

Phase 3

Merck Sharp & Dohme (MSD)

Charlotte, North Carolina, United States and 187 other locations

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

PK, and PD of SON-DP in participants with relapsed/refractory/intolerant to standard of care therapies, for advanced/ metastatic solid tumors...

Enrolling

Solid Tumor

Breast Cancer

Drug: SON-DP

Phase 1

Qurgen

Huntersville, North Carolina, United States of America and 4 other locations

Locations recently updated

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors...

Enrolling

Other Solid Tumors

Breast Cancer

Biological: Autologous, engineered T Cells targeting TP53 R175H

Phase 1

AstraZeneca

Charlotte, North Carolina, United States and 17 other locations

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (FRAmework-01)

Sofetabart Mipitecan (LY4170156) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A looks at ...

Enrolling

Ovarian Neoplasms

Fallopian Tube Neoplasms

Drug: MIRV

Drug: Sofetabart Mipitecan

Phase 3

Lilly

Charlotte, North Carolina, United States and 218 other locations

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (BOUQUET)

treatments in patients with persistent or recurrent rare epithelial ovarian, fallopian tube, or primary peritoneal tumors. Enrollme...

Active, not recruiting

Ovarian Cancer

Drug: Giredestrant

Drug: Cyclophosphamide

Phase 2

Roche

Charlotte, North Carolina, United States and 40 other locations

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms

Find clinical trials for Ovarian Cancer in .css-epvm6{white-space:nowrap;}Charlotte, NC

Related conditions:

Ovarian Cancer trials near Charlotte, NC, USA:

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (RAMP 301)

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST)

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 2)

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (FRAmework-01)

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (BOUQUET)

Find clinical trials for Ovarian Cancer in Charlotte, NC